NervGen Pharma Corp. announced the approval for listing on Nasdaq under the symbol “NGEN.” The company is developing neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic conditions. This follows the positive results from Phase 1b/2a CONNECT SCI Study, showing improvements in function, independence, and quality of life in chronic SCI. NervGen will conduct an FDA End-of-Phase 2 meeting in early 2026 for NVG-291. The lead candidate has Fast Track designation from the FDA and Orphan Drug designation from the EMA for SCI treatment. NervGen aims to transform the treatment paradigm for neurotraumatic conditions with significant unmet medical need.

(Source: Globe Newswire)

Read more at GlobeNewswire: NervGen Pharma Begins Trading on Nasdaq Today